A 5-year Observational Follow-up Study to Describe Treatment Patterns in Real World of HCV Patients in China.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01594554

Recruitment Status : Unknown

Verified May 2012 by Lai Wei, Peking University People's Hospital.
Recruitment status was: Recruiting

First Posted : May 9, 2012

Last Update Posted : May 10, 2012

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

Lai Wei, Peking University People's Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	April 2016
Estimated Study Completion Date :	September 2016

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wu N, Rao HY, Yang WB, Gao ZL, Yang RF, Fei R, Gao YH, Jin Q, Wei L. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl). 2020 Feb 5;133(3):253-261. doi: 10.1097/CM9.0000000000000629.

Rao H, Xie Q, Shang J, Gao Z, Chen H, Sun Y, Jiang J, Niu J, Zhang L, Wang L, Zhao L, Li J, Yang R, Zhu S, Li R, Wei L. Real-world clinical outcomes among individuals with chronic HCV infection in China: CCgenos study. Antivir Ther. 2019;24(7):473-483. doi: 10.3851/IMP3334.

To Top